chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It was reported that a 21 year old female pt received a Typhim Vi vaccine, date not specified. The pt has been in Africa since January 2002. She was diagnosed on 4/4/2002 with malaria and typhoid. Further info is requested. From f/up #1 correspondence received at manufacturer on 8/12/02 it was reported that the patient received the Typhim VI vaccination on 11/13/01, she also received an Imovax Rabies and a Fluzone SV '01-'02 vaccination that same day. *On 11/5/01* the patient was administered a Yellow Fever vaccination and a Imovax Rabies vaccination. On 12/4/01 the patient was administered an Imovax Rabies vaccination, an IPOL vaccination and a Menomune A/C/Y/W-135 vaccination. The patient was treated with Metloquine for the Malaria. *F/UP report on 11/5/02: F/UP #2 correspondence received on 10/25/02 indicated that Fluzone SV 2001-2003 USP were administered IM in the deltoid. No further info is available since the PT was not treated at the reporting facility. This case is closed.*
4 hours after vaccine back and join pain and fever, over 100.1, patient took ibuprofen and went to bed and woke up with 101.3. Patient also reports dry eyes
Tested positive for Covid.  Sore throat, head ache, fatigue, cough, stuffiness
Information has been received from a health professional concerning an approximately 2 month old male who, between 09-APR-2007 and 13-APR-2007, was vaccinated with a 2 ml, oral, first dose of rotavirus vaccine live (human-bovine) (lot# 656186/1235F). There was no illness at the time of vaccination. It was reported that the patient appeared to have a hard time swallowing the medication. The reporter felt that the vaccine was too thin and she was uncomfortable with the fact that the patient appeared to cough as a result of the administration. It was reported that the vaccine was administered very slowly and despite that the patient still choked. The patient recovered after the administration of rotavirus vaccine live (human-bovine). There were no laboratory or diagnostic tests performed. Unspecified medical attention was sought. No product quality complaint was involved. No other information was provided. Additional information is not expected.
This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. An 83-year-old female patient received BNT162b2 (BNT162B2), on 27Sep2021 as dose 3 (booster), single (Lot number: FC3184) at the age of 82 years, in arm, via needle route (as reported), for covid-19 immunisation. The patient's relevant medical history included: "Former smoker : No" (unspecified if ongoing), notes: Is the Patient a smoker/Former smoker : No. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Site of injection: Arm, Route: Needle (as reported), Batch/ Lot number: K63249), administration date: 21Jan2021, when the patient was 81-year-old, for Covid-19 immunization; BNT162b2 (DOSE 2, SINGLE, Site of injection: Arm, Route: Needle (as reported), Batch/ Lot number: EL9262), administration date: 11Feb2021, when the patient was 81-year-old, for Covid-19 immunization. The following information was reported: BREAST CANCER (medically significant) with onset 05Jan2022, outcome "unknown", described as "Breast Cancer -History of after 3rd Pfizer-BioNTech Covid 19 Shot". Clinical information: The patient received dose 4 of BNT162b2 on 12Apr2022 and experienced COVID-19 on 02Aug2022. During follow-up, the reporter answered following questions: Does the patient have a positive test for SARS-CoV2 reported as No. Dose the patient has SARS-CoV2 antibodies at diagnosis reported as No. Was/ Is the patient hospitalized reported as No. Was/ Is the patient admitted to an Intensive Care Unit reported as No. Is the patient still hospitalized reported as No. If discharged, did the patient have SARS-CoV2 antibodies at hospital discharge reported as No. Did the patient display signs at rest indicative of severe systemic illness reported as No. Did the patient require supplemental oxygen (including high flow or ECMO) or receive mechanical ventilation reported as No. Please provide information on any new or worsened symptoms/ signs during the Covid-19 illness experienced (including date of onset/ worsening): Multiorgan failure reported as No. Tachypnea: No. Hypoxemia: No. Covid-pneumonia: No. Respiratory failure: No. Other: Yes, Details: the patient stated, I did not have Covid. Cardiovascular: No. Heart failure: No. Cardiogenic shock: No. Acute myocardial infarction: No. Arrhythmia: No. Myocarditis: No. Other: No. Gastrointestinal/ Hepatic: No. Does the patient have a history of any of the following reported as Cancer (Breast (05Jan2022)). Did the patient provide information to you regarding the reported adverse event(s) with the use of the product reported as Yes. If yes above, do you considered the Pfizer product had a causal effect to the adverse event reported as Yes.
12/27/08 --> Lt scapular pain - gen OXYCONTIN 20mg. ? nerve root. 1/1/09 - shingles --> given FAMVIR 500mg: PO Q8 hours.
anaphylaxis within 10 minutes of immunizations administered - acute onset of cough without ability to catch breath, diminished lung sounds with bilateral breathing, epinephrine 0.2 mg IM administered with improvement but not resolution in lung sounds. Sent immediately to ED where patient received dose of albuterol nebulized.
Hives all over her body; Itching; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives all over her body) and PRURITUS (Itching) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (LOSARTAN/HYDROCHLOROTHIAZIDE), SIMVASTATIN and CITALOPRAM for an unknown indication.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, the patient experienced URTICARIA (Hives all over her body) and PRURITUS (Itching). At the time of the report, URTICARIA (Hives all over her body) and PRURITUS (Itching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
3 of her staff members tested positive after taking the 1st dose/They got a result for asymptomatic 3 employees that tested positive with COVID 19; 3 of her staff members tested positive after taking the 1st dose/They got a result for asymptomatic 3 employees that tested positive with COVID 19; This is a spontaneous report from a Pfizer Sponsored Program. A contactable Nurse reported similar events for 3 patients. This is 1st of 3 reports. A patient of unspecified age and gender received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 05Jan2021 at single dose for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient tested positive with COVID 19 on 11Jan2021. Outcome of events was unknown.   Information about lot/batch number has been requested.; Sender's Comments: The patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) on 05Jan2021, and tested positive with COVID-19 on 11Jan2021.  No complete protection of the suspect vaccine could be reasonably achieved to prevent from the targeted infection due to the very short time lag. The positive COVID-19 is more likely pre-existing infection prior to vaccine use, and unrelated to BNT162B2 based on the limitedly available information.,Linked Report(s) : US-PFIZER INC-2021049694 Pfizer, Same drug, same event, different patient;US-PFIZER INC-2021049695 Pfizer, Same drug, same event, different patient
Immunization given 11/6/08, very painful arm during night w/ rash. AM pt noted hot to touch. Evaluated by MD on 11/7/08- erythema, heat, swelling, tenderness at injection site and distally down right arm. Temperature 36.4. 11/10/08 Pt reports much better.
Day 1-3: red injection site, sore arm and body aches, fatigue  Day 4-5: red injection site but otherwise fine  Day 6-7: red injection site hot to touch, itching, getting larger  Day 8: injection site 4? diameter red swollen, itching and burning (COVID arm)
Hives (face, neck, ribcage, stomach, arms, hands, back, legs, underarms, elbows), Swollen eyes; Swollen lips; Hard Ears; Warm Skin; Itching; Wheezing.
10/5/2022   The first week of October began to feel ill.  Lost voice and Dry Cough, occasional coughing up phlegm, and some nasal drainage.  Night Sweats.  11/11 Went to Urgent Care, Doctor ran a test for strep, Negative.  Negative for COVID-19.  Prescribed methylprednisolone.  After 2 days of taking that there was a great improvement.   Participant felt sick again 12/21.  Symptoms were mild until 12/28 when they got considerably worse.  Phlegm is dark green and much thicker this time.  This brings us to the present.
Administered dose from punctured vial left out at room temperature for over 9 hours; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 Vaccine (mRNA-1273), and who was administered dose from punctured vial left out at room temperature for over 9 hours.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On an unknown date, the patient received a dose of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection.  On 05 Jan 2021, a pharmacist reported that the facility's clinic administered a dose of the vaccine to a patient from a punctured vial that was left out at room temperature for 9 hours. The pharmacist was unable to provide any information about the patient or vial. No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not reported.  The event, administered dose from punctured vial left out at room temperature for over 9 hours, was considered resolved on an unknown date.   The reporter did not provide an assessment for the event, administered dose from punctured vial left out at room temperature for over 9 hours.; Reporter's Comments: This report refers to a case of a patient administered dose from punctured vial left out at room temperature for over 9 hours (Expired product administered) for mRNA-1273. Lot #  was not provided. There were no reported adverse events associated with this case of administered dose from punctured vial left out at room temperature for over 9 hours
Woke with headache several nights starting about 3 weeks after vaccine, nausea, loss of appetite. Off and on for 10 days-2 weeks.  (One day particularly bad (12/3).  Stayed in dark room all day, headache, fatigue, vomited x1).  Consulted with advice nurse & MD, lots of lab work came back normal. Feeling better. Doc thought viral. (I?m not at all sure it was vaccine related but the question was MIGHT it be. Who knows? That?s what you?re figuring out. :) Thank you.)
Fever, vomiting, fussy, crying.  Onset about 1 hour after injections.  Knot at injection site.  Mom took child to hospital.  Tylenol and Pedialyte, mom monitoring.
Fever Chills and sweating Tachycardia Dizziness  Took Tylenol
A knot at injection site persisted for 4-5 months followed by failure to thrive, hypotonia, eye tracking problems, hand tremors and digestion problems. She required 10 months of physical therapy to get strong enough to walk. She ended up walking at 21 months. We now know that these symptoms match aluminum toxicity. Aluminum is a known neuro-toxin. Her symtpoms were neurological for the most part.
April 2021 began with severe pain in toes in  bilateral worse at end of day, night.  July 2021 symptoms progressed to foot pain bilateral and fatigue.  Tried heat, Tylenol, Advil.  Worsening pain.  By January 2022, pain was so excruciating with inability to sleep appointment given for May 2022 with PCP.   Started me on gabapentin 100 mg, at night.   Referred to neurology who thought it was vascular problem.  Testing negative for vascular. Vascular sent me back to neurology.  Severe peripheral neuropathy diagnosed.  thought it could be a side effect to Keppra.  Stopped Keppra and depakote restarted.   Worsening symptoms,  pain now in bilateral lower extremities and weakness.  EMG and spinal tap done.  CIDP diagnosed 2/2023.  Treatment with IVIg started March 20.2023.  Physical therapy started 4/2023.  Advil and Tylenol prn for increased pain and inflammation.  Gabapentin to 300 mg at bedtime.  Treatment has stopped the progression of CIDP symptoms.  Pain has decreased after IVIg for 3 weeks.  Then flare up with severe pain.  Then infusion with IVIG, two days after symptoms decrease to tolerable pain and weakness intermittently decreased with physical therapy.
The pt experienced a fever, headache, body aches, tingling and tenderness to the touch. The MD has advised no more TD vaccinations.
Patient was under the recommended age for the vaccine - Mother knowingly consented and lied about age of patient
Chills; headache; muscle and joint pain; muscle and joint pain; tiredness; nausea; Like a mild flu; This is a spontaneous report from a contactable other healthcare professional (patient). A 64-year-old female patient received the second dose of bnt162b2 (BNT162B2, lot number: EL 8982, expiry date: not reported), via an unspecified route of administration, on 26Jan2021 12:15 PM at a single dose on the right arm for COVID-19 immunization. The patient did not receive any other vaccine in four weeks prior to receiving bnt162b2. The patient was not pregnant. She was not diagnosed with covid prior to vaccination. Medical history included high bp (blood pressure) and type 2 diabetes. The patient previously received the first dose of bnt162b2 (BNT162B2, lot number: EL 1284, expiry date: not reported), on 05Jan2021 10:30 AM on the right arm for COVID-19 immunization (at the age of 64-year-old). On 26Jan2021 04:30 PM, the patient experienced chills, headache, muscle and joint pain, tiredness, nausea; like a mild flu. No treatment was received for the events. Outcome of the events was recovering. The patient was not tested for covid post vaccination.   No follow up attempts are possible. No further information is expected.
Developed a welt, red, itchy, hot to touch rash after receiving the Covid vaccine that night 1/8/21. Was the size of a quarter and as of now 1/18/2021 is the size of a dollar. Have been taking otc Benadryl and icing the area. Next day after vaccine was not feeling well ever since. Positive for Covid 1/17/21 fever 101, headache, chills, body aches, bones hurt all over, congestion, runny nose, cough, sore throat, breathing problems, pain left side chest, vomiting, lost of smell
This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of ARTHRALGIA (joint ache), MYALGIA (muscle ache), DIARRHOEA (diarrhea), COUGH (slight cough) and OROPHARYNGEAL PAIN (sore throat) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced ARTHRALGIA (joint ache), MYALGIA (muscle ache), DIARRHOEA (diarrhea), COUGH (slight cough) and OROPHARYNGEAL PAIN (sore throat). On 10-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (COVID -19 test positive). The patient was treated with NAPROXEN SODIUM (ALEVE) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, ARTHRALGIA (joint ache), MYALGIA (muscle ache), DIARRHOEA (diarrhea), COUGH (slight cough), OROPHARYNGEAL PAIN (sore throat) and SARS-COV-2 TEST POSITIVE (COVID -19 test positive) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.; Sender's Comments: Very limited information regarding this event has been provided at this time. The patient probably experienced asymptomatic COVID-19 infection before being administered with the mRNA-1273 vaccine.
Initial and follow up information has been received from a RN and a clinical manager, concerning a male with senile dementia, who on an unspecified date was vaccinated IM in the left thigh with a 0.5ml dose of pneumococcal 23v polysaccharide vaccine (lot not reported). Post vaccination, the pt was unable to move his leg. The nurse was not sure if the vaccination caused the problem because the pt had other (issues). Unspecified medical attention was sought. No product quality complaint was involved. Follow up information indicated that after vaccination, the pt complained of pain, soreness at the injection site, and he refused to walk. It was confirmed that the pt never lost the ability to walk. At the time of the report the pt had recovered from the pain, soreness at the injection site. Additional information is not expected.
Patient received his 1st COVID vaccine (Pfizer, lot # EW0182 use by 5/15/21 at 0855) at 1539. The patient became pale approximately 30 seconds following the administration of the vaccine, EMT assisted the patient to the chair as he was standing up when he became pale, the patient loss consciousness for approximately 2 seconds. RN arrived at the station and assisted the patient to the ground, where he was placed in a supine position with his lower extremities elevated. The patients face mask was removed, he was alert and oriented to person, place, time, and situation. The patients color slowly returned to his face. Vitals were taken at 1540: BP: 155/70 (R arm, supine position), HR 70, RR 16, oxygen saturation at 97%, and pupils were equal. The patient had a history of fainting x 1 and his last meal was at 0800 and he stated, " I didn't drink that much today." Denied any chronic medical conditions, was not currently taking any medications, and denied any drug allergies. The patient was moved to the anti-gravity chair and he was given pringles and Gatorade. Vitals were retaken at 1545: BP 162/80 (R arm, sitting upright), HR 50, RR 16, oxygen saturation at 97%. Denied any dizziness, headache, chest pain, or vision changes.  Vitals were retaken at 1553: BP 158/72 (R arm, sitting upright), HR 52, RR 16, Oxygen saturation at 97%. The patient was advised to eat a full meal prior to receiving his second COVID vaccine dose and to receive his 2nd dose in the anti-gravity chair. Vitals were retaken at 1558, BP 152/78 (R arm, sitting upright), HR 57, RR 16, and oxygen saturation at 98%. The patient was also given a bottle of water, as he did not consume many liquids during the day. The patient's color fully returned to his face and he denied any shortness of breath, dizziness, changes in vision, or difficulty swallowing. Vitals retaken at 1603, BP 150/75 ( R arm, sitting upright), HR 60, RR 16, and oxygen saturation at 96%. The patient called his mother to pick him up, as we strongly advised him to not operate machinery/ a vehicle after fainting. The patient's vital signs were taken at 1608, BP 140/75, HR 60, RR 16, and oxygen saturation at 100%. The patient was advised to drink the entire bottle of water, as his blood pressure was slightly elevated and it was most likely due to being dehydrated, as he did not consume any fluid since 0800 earlier that day. The patient drank a bottle of water and his vital signs were retaken at 1614, BP 122/68 (R arm, sitting upright) and a respiratory rate of 15 breaths per minute. The patient's mother arrived on site around 1630 and spoke with RN and both EMT. RN instructed the patient about emergency precautions and to follow up with his primary care provider. RN also educated the patient about the importance of informing the healthcare provider about his history of fainting with the first vaccine, when receiving the second COVID Pfizer vaccine. Gave the patient V-safe information and reported the occurrence in VAERS. The patient had a steady and even gait when leaving the site with his mother at 1632.
I don't have lot number or dose number.  It was a Moderna COVID 19 vaccine.  I got my first dose on Jan 11, 2021, suffered light headedness the first day, and two days later, while at work I felt like I was going to pass out several times.  I also suffered low grade fever and swelling of my lymph glands in my throat.  I took my booster on Feb 8, 2021 at 1310, the next morning I was suffering nausea and overall malaise.  I waited until fever started to take alternating tylenol and motrin.  I was very weak, freezing to death, and fell asleep about 6 PM fully dressed with my coat on under covers.  I woke up at 9 pm, still feeling horrible, wondering if it was 9 am or 9 pm, and went back to sleep until 715 am this morning with body feeling like it was ran through a hamburger grinder, no doubt a result of the shivering yesterday.  I have not had fever today, but still feeling a little nauseous about eating anything.
Swelling of injection site.  Swelling was about 1.5 inch in diameter, painful to touch and slightly hot to touch.  Swelling and pain lasted for about 10 days with first 5 days very painful to touch affecting sleep.   Also had bruising of about 3/4 inch diameter about 2 inches above injection site.
About 10 minutes after receiving vaccine, pt started complaining of sharp pains in back and stomach. Administered epinephrine autojector and contacted EMS. Patient was transferred to hospital for monitoring. Per pt's daughter she was monitored and then discharged home.
Temp of 103 sometime after vaccines, presented to ER at 1833 with febrile seizure lasting approx. 1 minute.
She became ridged and pupils dilated and had some involuntary movements of arms and legs lasted  about 8 sec. Client then regained conciseness . She states she was light headed and felt like she passed out and woke up. Client monitored for 30 minutes and then was released to go home. PCP notified.
Severe, debilitating stomach pain, muscle weakness in legs, sore throat, nausea, headache.
Swelling on injection site. swelling feels warm and itchy. Fever the day after vaccine and pain in body.
No additional AE reported; HCP called to report they inadvertently administered expired PROQUAD vaccine to a patient on 8/14/2023; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 14-AUG-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 1 dosage form, lot #W004694 rHA, expiration date: 08-AUG-2023 (Expired product administered), administered for prophylaxis (strength, and route of administration were not provided).  No adverse symptoms were reported.